(NASDAQ: IKNA) Ikena Oncology's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Ikena Oncology's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast IKNA's revenue for 2028 to be $1,109,936,553, with the lowest IKNA revenue forecast at $1,109,936,553, and the highest IKNA revenue forecast at $1,109,936,553. On average, 1 Wall Street analysts forecast IKNA's revenue for 2029 to be $2,798,970,438, with the lowest IKNA revenue forecast at $2,798,970,438, and the highest IKNA revenue forecast at $2,798,970,438.
In 2030, IKNA is forecast to generate $4,536,262,434 in revenue, with the lowest revenue forecast at $4,536,262,434 and the highest revenue forecast at $4,536,262,434.